Sanofi acquires rights to develop aficamten for hypertrophic cardiomyopathy in Greater China

From GlobeNewswire: 2024-12-20 00:00:00

Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatment of hypertrophic cardiomyopathy in Greater China. Aficamten is a cardiac myosin inhibitor with Breakthrough Therapy Designation for oHCM in China.

Sanofi will acquire Corxel’s rights to aficamten in Greater China for an undisclosed amount. Cytokinetics could receive up to $150 million in milestone payments from Sanofi, as well as royalties on future sales of aficamten in Greater China.

Aficamten is a next-in-class cardiac myosin inhibitor being evaluated in clinical trials for HCM treatment. It received Breakthrough Therapy Designation from the FDA and is being considered for approval in China and Europe.

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disorder affecting approximately 280,000 patients in the US, with many more undiagnosed. Aficamten aims to improve symptoms and exercise capacity in HCM patients.

Cytokinetics is a biopharmaceutical company focused on developing treatments for diseases affecting cardiac muscle performance. Aficamten is one of their potential treatments for hypertrophic cardiomyopathy.

Cytokinetics disclaims any intent to update forward-looking statements regarding the development and commercialization of their drug candidates. They advise investors to consult their regulatory filings for more information on potential risks and uncertainties.

References: CVrg: Heart Failure 2020-2029, Maron et al. 2013, Symphony Health 2016-2021 Patient Claims Data, Gersh et al. 2011, Hong et al. 2022.

For more information, contact Cytokinetics’ Senior Vice President, Corporate Affairs, Diane Weiser at (415) 290-7757.



Read more at GlobeNewswire: Cytokinetics Announces Sanofi Acquired Rights to Develop